<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305355</url>
  </required_header>
  <id_info>
    <org_study_id>08-OM-9412</org_study_id>
    <nct_id>NCT02305355</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia</brief_title>
  <official_title>Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuhnil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in
      subjects with type 2 Diabetes combined with hyperlipidemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean percent change of Triglyceride(TG)</measure>
    <time_frame>from baseline at week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Total Cholesterol(TC)</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of LDL-C</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of HDL-C</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of HBA1c</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of FPG</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of hs-CRP</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of PAI-1</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Apolipoprotein A1</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of apolipoprotein B</measure>
    <time_frame>from baseline at week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertriglycemia</condition>
  <arm_group>
    <arm_group_label>Omega-3-acids ethylesters 90 4g, any statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>any statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-acids ethylesters 90 4g</intervention_name>
    <arm_group_label>Omega-3-acids ethylesters 90 4g, any statin</arm_group_label>
    <other_name>Omacor Soft Capsule 4g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin</intervention_name>
    <arm_group_label>Omega-3-acids ethylesters 90 4g, any statin</arm_group_label>
    <arm_group_label>any statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL-C &lt; 100mg/dL, TG &gt; 150mg/dL, patients on statin treatment for at least 6 weeks
             prior to randomization.

          -  Type 2 Diabetes

          -  HbA1c ≤ 10.0

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Patients with PPAR gamma agonist therapy

          -  Patients with acute MI, Unstable angina within 6 months

          -  History of malignant tumor within 2 years

          -  Women with pregnant, breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

